Evidence map›Paper›PMID 29670004›Full record

ArticleToxins2018

Analogs of the Scorpion Venom Peptide Stigmurin: Structural Assessment, Toxicity, and Increased Antimicrobial Activity.

Adriana M S Parente, Alessandra Daniele-Silva, Allanny A Furtado, Menilla A Melo, Ariane F Lacerda, Moacir Queiroz, Cláudia Moreno, Elizabeth Santos, Hugo A O Rocha, Euzébio G Barbosa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Antifungal activity ofToxicon: X · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Antimicrobials from Venomous Animals: An Overview.Molecules (Basel, Switzerland) · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Adriana M S ParenteLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. adrianamsparente@gmail.com.
Alessandra Daniele-SilvaLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. alessandra.daniele@outlook.com.
Allanny A FurtadoLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. allannyfurtado@hotmail.com.
Menilla A MeloLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. menillamam@outlook.com.
Ariane F LacerdaLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. arianeflacerda@gmail.com.
Moacir QueirozPrograma de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil. moacirfqn@gmail.com.
Cláudia MorenoPrograma de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil. claudia.mrn1@gmail.com.
Elizabeth SantosLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. elizabethcgsantos@gmail.com.ORCID 0000-0003-4912-8016
Hugo A O RochaPrograma de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil. hugo-alexandre@uol.com.br.
Euzébio G BarbosaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil. euzebiogb@gmail.com.ORCID 0000-0002-7685-9618
Eneas CarvalhoInstituto Butantan, São Paulo 05503-900, SP, Brazil. eneas.carvalho@butantan.gov.br.
Arnobio A Silva-JúniorLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. arnobiosilva@gmail.com.
Marcelo S SilvaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil. mssilva.ufrn@gmail.com.
Matheus de F Fernandes-PedrosaLaboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil. mffpedrosa@gmail.com.ORCID 0000-0003-4221-9580
Universidade Federal do Rio Grande do Norte · BRInstituto Butantan · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scorpion venom is a rich source of biologically active components and various peptides with high-potential therapeutic use that have been characterized for their antimicrobial and antiproliferative activities. Stigmurin is a peptide identified from the

Indexed as

3T3 CellsAmino Acid SequenceAnimalsAnti-Infective AgentsBacteriaCandidaCell ProliferationErythrocytesHeLa CellsHumansMiceMolecular Dynamics SimulationPeptidesProtein Structure, SecondaryScorpion VenomsTrypanosoma cruziAnti-Infective AgentsPeptidesScorpion Venomsstigmurin, Tityus stigmurusanalog peptidesantimicrobial peptideantiparasiticantiproliferativescorpion venomStigmurinstructure-activity relationship

Identifiers

PMID29670004
PMCPMC5923327
OpenAlexW2802301476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.